RxDoctor Payments Data

Christopher Walters, MD

Cardiovascular Disease · Lumberton, NCNPI 1053461319

Payments from drug & device makers

$158,844in general payments, 2019–2025

Across 112 payments — averaging $1418.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$76K
  • Merck$57K
  • CSL Behring$25K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$427
  • Novartis$154
  • Johnson & Johnson$103
  • plus $622 from 15 others

What the payments were for

  • Food & beverage$1,306100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$158,844 in reported general payments places this provider in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$144,528
Medicare patients
731
Services billed
1,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban336$300,811
EntrestoSacubitril/Valsartan165$159,097
Repatha SureclickEvolocumab107$96,349
JardianceEmpagliflozin85$84,424
XareltoRivaroxaban41$32,548
BrilintaTicagrelor25$16,653
Praluent PenAlirocumab16$15,421
FarxigaDapagliflozin Propanediol14$11,485
Metoprolol Succinate324$3,352
Amiodarone Hcl69$3,086
Atorvastatin Calcium258$2,544
ClopidogrelClopidogrel Bisulfate225$2,523
Flecainide Acetate67$2,391
Rosuvastatin Calcium184$2,154
Ranolazine ErRanolazine38$2,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$83$300,811336 claims
NovartisEntresto$154$159,097165 claims
Boehringer IngelheimJardiance$67$84,42485 claims
Johnson & JohnsonXarelto$103$32,54841 claims
AstraZenecaBrilinta, Farxiga$68$28,13839 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Lumberton

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →